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Abstract
Adenoviral (Ad) vectors have been used for a variety of vaccine applications including cancer and infectious diseases.
Traditionally, Ad-based vaccines are designed to express antigens through transgene expression of a given antigen.
However, in some cases these conventional Ad-based vaccines have had sub-optimal clinical results. These sub-optimal
results are attributed in part to pre-existing Ad serotype 5 (Ad5) immunity. In order to circumvent the need for antigen
expression via transgene incorporation, the ‘‘antigen capsid-incorporation’’ strategy has been developed and used for Ad-
based vaccine development in the context of a few diseases. This strategy embodies the incorporation of antigenic
peptides within the capsid structure of viral vectors. The major capsid protein hexon has been utilized for these capsid
incorporation strategies due to hexon’s natural role in the generation of anti-Ad immune response and its numerical
representation within the Ad virion. Using this strategy, we have developed the means to incorporate heterologous
peptide epitopes specifically within the major surface-exposed domains of the Ad capsid protein hexon. Our study herein
focuses on generation of multivalent vaccine vectors presenting HIV antigens within the Ad capsid protein hexon, as well
as expressing an HIV antigen as a transgene. These novel vectors utilize HVR2 as an incorporation site for a twenty-four
amino acid region of the HIV membrane proximal ectodomain region (MPER), derived from HIV glycoprotein gp41 (gp41).
Our study herein illustrates that our multivalent anti-HIV vectors elicit a cellular anti-HIV response. Furthermore,
vaccinations with these vectors, which present HIV antigens at HVR2, elicit a HIV epitope-specific humoral immune
response.
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Introduction
Adenoviral (Ad) vectors have been used for a variety of vaccine
applications including cancer and infectious diseases [1–4]. Ad
vectors have been utilized as vaccine vectors because of several
attributes. This broad utility profile has derived from several key
attributes: (a) the viral genome is readily manipulated allowing
derivation of recombinant viruses; (b) replication-defective Ads can
be derived and propagated easily in complementing cell lines
making production of large scale vaccines feasible; (c) Ads infect a
broad range of target cells [5,6]; (d) they possess a large gene
delivery payload of up to 8kb; and (e) the vector can achieve
unparalleled levels of in vivo gene transfer with high levels of
induced transgene expression [6,7]. Traditionally, Ad-based
vaccines have been designed to express antigens through transgene
expression of a given antigen [8]. However, in some cases these
conventional Ad-based vaccines have had sub-optimal clinical
results. These sub-optimal results are attributed in part to pre-
existing Ad serotype 5 (Ad5) immunity. 50–90% of the adult
population has pre-existing immunity (PEI) to Ad5 and therefore,
if an individual is vaccinated with an Ad vector for therapeutic
purposes there maybe limited transgene/antigen expression in that
individual [9–13]. In this regard, the ‘‘antigen capsid-incorpora-
tion’’ strategy has been developed to circumvent drawbacks
associated with conventional transgene expression of antigen
within Ad. This strategy embodies the incorporation of antigenic
peptides within the capsid structure of viral vectors. This antigen
capsid-incorporated strategy has been used for Ad-based vaccines
in the context of many diseases [4,14–18]. One of the first
instances whereby the antigen capsid-incorporation strategy was
used was in research performed by Crompton in 1994. Crompton
and colleagues inserted an eight amino acid sequence of the VP1
capsid protein of poliovirus type 3 into two regions of the
adenovirus serotype 2 hexon. One of the chimeric vectors
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11815produced from this methodology grew well in tissue culture and
antiserum raised against the Ad with the polio insert specifically
recognized the VP1 capsid of polio type 3.
Using this antigen capsid-incorporation strategy, we have
developed the means to incorporate heterologous peptide epitopes
specifically within the major surface-exposed domains of the Ad
capsid protein hexon. The major capsid protein hexon has been
utilized for these antigen capsid incorporation strategies due to
hexon’s natural role in the generation of anti-Ad immune response
and its numerical representation within the Ad virion [4,14,15,
17–21]. Of note, our previous work has shown that we can
incorporate small heterologous peptides into Ad hexon hypervari-
able regions (HVRs) without perturbing viral viability and other
biological characteristics [19]. Published studies have focused on
antigen and/or epitope incorporations at HVR5 or single site
antigen/epitope incorporation at fiber or protein IX (pIX) [22]. In
this regard, antigenic epitopes including linker sequences ranging
in size from nine to forty-five amino acids have been incorporated
within the Ad5 hexon region or Ad2 hexon region. These epitope
incorporations include epitopes derived from polio, Pseudomonas
aeruginosa,B .anthracis, and HIV as well as model epitopes
[4,15,16,18]. Based on our ability to manipulate both HVR2
and HVR5 sites, recently we sought to explore the relative merits
of antigen incorporation within these two hexon locales. In order
to accomplish this we compared the flexibility and capacity of
HVR2 and HVR5, respectively. We genetically incorporated
identical model epitopes of increasing size within HVR2 or HVR5
of the Ad5 hexon. Our previous study demonstrated that hexon-
incorporated model antigens elicit a range of immune responses
depending on antigen placement or antigen size at either the
HVR2 or HVR5 locales. This study confirmed that HVR2 could
be a potential incorporation site for antigens of considerable size
and that vaccination with vectors that display incorporations at
HVR2 is feasible for vaccine development [16].
Our study herein focuses on the creation of multivalent vaccine
vectors presenting HIV antigens in the context of the Ad capsid
protein hexon, as well as expressing HIV antigens as a transgene.
Specifically, these novel vectors utilize the hexon HVR2 as an
incorporation site for a twenty-four amino acid region (EKNE-
KELLELDKWASLWNWFDITN) of the HIV membrane prox-
imal ectodomain region (MPER), derived from HIV glycoprotein
gp41 (gp41). In addition, to presenting MPER within HVR2 these
vectors express HIV-specific protein Gag from the Ad5 DE1
region. Our study herein illustrates that our multivalent anti-HIV
vectors elicit a humoral and cellular anti-HIV response.
Furthermore, vaccinations with these vectors, which present




For these studies HIV-1 gp41 monoclonal antibody (2F5), cat#
1475 was used. The following reagent was obtained through the
NIH AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH: HIV-1 gp41 Monoclonal Antibody (2F5)
was generated by Dr. Hermann Katinger. The human monoclo-
nal antibody to HIV-1 gp41 is specific for ELDKWA epitope
[23–25]. Goat anti-human horse radish peroxidase (HRP) anti-
body was purchased from Southern Biotech. (Birmingham, AL).
Cell culture
Human embryonic kidney cells (HEK293) were obtained from
and cultured in the medium recommended by the American Type
Culture Collection (Manassas, VA). All cell lines were incubated at
37uC and 5% CO2 under humidified conditions.
Recombinant adenovirus construction
In order to generate recombinant adenoviruses with the MPER
insertions within the hexon regions, fragments of DNA corre-
sponding to MPER, were generated by PCR from templates
provided by Integrated DNA technologies. In our manuscript, the
MPER sequence corresponds to EKNEKELLELDK-
WASLWNWFDITN from HIV gp41. This fragment was
subcloned into the BamHI site in the previously described
HVR2-His6/pH5S plasmids [19]. To create Ad5 vectors contain-
ing HIV epitopes in the HVRs of hexon, these resulting plasmids
were digested with EcoRI and PmeI. These resulting fragments
containing the homologous recombination regions and the hexon
genes were purified, then recombined with a SwaI-digested Ad5
backbone vector that lacks the hexon gene, pAd5/DH5 [26].
These recombination reactions were performed in Escherichia coli
BJ5183 (Stratagene, La Jolla, CA). The resultant clone was
designated as Ad5/HVR2-MPER-L15; in addition, there was
another virus construct with this hexon modification, which
contained the HIV Gag gene in the DE1 region: Ad5/HVR2-
MPER-L15 (Gag). To create Ad5 vectors containing HIV Gag,
the cytomegalovirus (CMV)-Gag construct was subcloned into an
Ad DE1 shuttle plasmid. The resulting plasmid was digested with
PmeI restriction enzyme. The resulting fragment containing the
homologous recombination region at the Ad5 DE1 region was
then recombined with the E1 deleted Ad5 backbone. AdCMVEnv
was made as previously described [27], This vector expresses the
HIV 89.6 envelope (Env) gene under the control of the CMV
promoter.
Virus rescue and preparation
To rescue viruses the constructed plasmids were digested with
PacI and two mg DNA were transfected (Lipofectamine 2000
Reagent, Invitrogen, Carlsbad, CA) into the Ad-E1-expressing
HEK293 cells. Following plaque formation, they were processed for
large-scale propagation in HEK293 cells. Viruses were purified by
double cesium chloride ultracentrifugation and dialyzed against
phosphate-buffered saline containing 10% glycerol. Viruses were
stored at 280uC until use. Final aliquots of virus were analyzed
for physical titer using absorbance at 260 nm. The infectious viral
titer (IFU) per ml was determined by tissue culture infectious dose
(TCID50)assay.TheTCID50 titerwascalculatedbyusingKARBER
statistical method: T TCID50 titer =10610
1 + d(S 2 0.5)/ml, in which
d is the log 10 of the dilution and S is the sum of ratios from the first
dilution. Modifications of the hexon gene was confirmed by PCR
analysiswiththe primers59HVR2(sense),CTCACGTATTTGGG-
CAGGCGCC and 3’HVR5 (antisense), GGCATGTAAGAAA-
TATG AGTGTCTGGG, which anneal up and downstream of the
site of the insertion within the hexon open reading frame.
Western blot analysis
To analyze Gag expression, in brief, 1610
6 HEK293 cells were
infected with various vectors at 100 IFU per cell. Cell lysates were
collected after 24 hours and subjected to four freeze-thaw cycles to
obtain crude cell lysate. 10 mg of protein was boiled in Laemmli
sample buffer for 10 minutes and resolved on 4 to 15% sodium
dodecyl sulfate-polyacrylamide gel. The proteins were transferred
to polyvinylidene fluoride membrane and staining was performed
with Gag antibody (1:1,000) (Affi-anti-HIV matrix IgY, Genway
Biotech, Inc.), followed by secondary staining with HRP-linked
goat-chicken IgY (1:2,000) (Aves Lab, Inc). The proteins were
detected on the polyvinylidene fluoride membrane by staining
Antigen Incorporation at HVR2
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MO).
In brief, to analyze MPER presentation on selected vectors,
10
10 viral particle (VP) were boiled in Laemmli sample buffer for
10 minutes and resolved on 4 to 15% sodium dodecyl sulfate-
polyacrylamide gel. The proteins were transferred to polyvinyli-
dene fluoride membrane and staining was performed with HIV-1
gp41 monoclonal antibody (2F5) (1:1,000). Followed by secondary
staining with HRP-conjugated goat anti-human antibody
(1:2,000). The proteins were detected on the polyvinylidene
fluoride membrane by staining with 3939-diaminobenzidine tablets
(Sigma-Aldrich, St. Louis, MO).
Whole virus ELISA and sera ELISA
The enzyme-linked immunosorbent assay (ELISA) was per-
formed essentially as described previously [28]. In order to
determine if the MPER peptide was surface exposed on the Ad
virion whole virus ELISA was performed. Briefly, different
amounts of viruses ranging from 4610
6 to 9610
9 VPs were
immobilized on 96-well plate (Nunc Maxisorp, Rochester, NY) by
overnight incubation in 100 ml of 100 mM carbonate buffer
(pH 9.5) per well at 4uC. After washing with 0.05% Tween 20 in
Phosphate-buffered saline (PBS) and blocking with blocking
solution (2% bovine serum albumin and 0.05% Tween 20 in
PBS), the immobilized viruses were incubated with anti-HIV 2F5
monoclonal antibody (cat# 1475) for 2 hr at room temperature
(RT) followed by incubation with an AP-conjugated goat anti-
human antibody. Colormetric reaction was performed with p-
nitrophenyl phosphate (Sigma-Aldrich, St. Louis, MO) as
recommended by the manufacturer, and optical density at
405 nm (OD405nm) was determined with a microplate reader
(Molecular Devices).
For the anti-MPER response ELISA plates (Nunc Maxisorp,
Rochester, NY) were coated with 10 mM of the MPER peptide
(GenScript Co, Piscataway, NJ) in 100 ml of 50 mM carbonate
(pH 9.6) per well, according to the method we described
previously [29]. Plates were washed and then blocked with 3%
BSA/PBS. After washing, 60 ml of 1:20 diluted sera was added.
After incubation for at least 2 hr at RT, the plates were extensively
washed and blocked with 3% BSA/PBS. The plates were then
washed with HRP-conjugated goat anti-human antibody (South-
ern Biotech, Birmingham, AL). ELISAs were developed with
TMB substrate. In order to determine MPER isotype-specific
reactivity, ELISA plates were coated with 10 mM of the MPER
peptide in 100 ml of 50 mM carbonate (pH 9.6) per well,
according to the method we described previously [29]. Plates
were washed and then blocked with 3% BSA/PBS. After washing,
60 ml of 1:20 diluted sera was added. After incubation for at least
2 hr at RT, the plates were extensively washed and blocked with
3% BSA/PBS. Isotype-specific mouse antibody (Sigma-Aldrich,
St. Louis, MO) was then bound to ELISA plates. Plates were then
washed and HRP-conjugated anti-mouse antibody (Dako Den-
mak, Denmark). ELISAs were developed with TMB substrate
(Sigma-Aldrich, St. Louis, MO). OD450nm was measured on an
Emax microplate reader.
Growth kinetics
Growth kinetics of Ad vectors were obtained essentially as
described previously [26]. HEK293 cells were plated in 6-well
plates at the density of 3610
5 cells per well 24 h before infection.
The cells were infected with Ads at 5 VPs/cell in 500 ml growth
medium containing 2% FBS. 1.5 ml more growth medium
containing 10% FBS was then added into each well after 2 h
incubation at 37uCi n5 %C O 2 humidified incubator. The infected
cells were monitored and harvested with medium at various time
points post-infection until complete CPE was formed. The
collected cells together with the medium were lysed by four
freeze–thaw cycles, and subjected to centrifugation at 3000 6g for
30 min at 4uC for cell debris removal. The total viruses in each
well were determined by multiplying TCID50 titer with the total
volume of the supernatant, and plotted as growth curves.
Thermostability
Heat inactivation assay was performed essentially as described
previously [19,26,30,31]. Briefly, viruses were incubated at 45uC
for 0, 5, 10, 20 or 40 min in either PBS (without Ca
2+ and Mg
2+)
or growth medium containing 2% FBS. Then their infectious titers
were re-determined by standard TCID50 method (AdEasy vector
system, Qbiogene Inc., Carlsbad, CA). One day before analysis
10
4 293 cells plus 100 ml of growth medium with 2% Fetal Bovine
Serum (FBS) were added in 96-well flat bottom plates. Eight serial





were made in medium containing 2% FBS depending on the virus,
and 100 ml of each dilution was added into 96-well plates, one row
for each dilution. After incubation for 10 days at 37uCi n5 %C O 2
humidified incubator the plates were examined for cytopathic
effect (CPE) under microscope. Observable CPE containing wells
were counted for each row in order to determine the ratio of
positive wells per row in the 96-well plates. Titer was calculated by
using TCID50.
Mouse immunization
The following experiment was performed to determine antibody
response after immunization with Ad vectors. Female BALB/c (H-
2K
d) mice at 6–8 weeks of age were obtained from the Jackson
Laboratory (Bar Harbor, ME). Groups of at least eight mice were
analyzed in each experiment or at each time point. Ads were
injected into each group of mice: Ad5, Ad5/HVR2-MPER-
L15(Gag), Ad5/HVR2-MPER-L15DE1, AdCMVGag, Ad-
CMVEnv at 1610
10 VP per mouse using intramuscular (i.m.)
injection. These mice were boosted 14 days after prime with
1610
10 VP of the same vector. For CD8 T cell response analysis,
blood was collected from mice vaccinated with Ad5/HVR2-
MPER-L15(Gag) or AdCMVGag. All animal protocols were
approved by the Institutional Animal Care and Use Committee at
the University of Alabama at Birmingham.
MPER peptide synthesis
The antigenic epitope of HIV MPER derived from gp41 was
generated in an expression plasmid by (GenScript Co, Piscataway,
NJ). This peptide was used as a positive control for the ELISA
assays. Peptides were .98% pure as indicated by analytical high-
performance liquid chromatography. Peptides were dissolved in
100% DMSO at a concentration of 10 mM and stored at 220uC
until use.
Flow cytometry
For flow cytometric analysis of HIV-1 Gag gene expression, 10
6
293AD cells (Qbiogene Inc.) were infected at 10 VP/cell with
either AdCMVGag or Ad5/HVR2-MPER-L15(Gag) Ad vectors
for 24 hours in the presence of different amounts of human ascites
and then cells were permeabilized with Cytofix/Cytoperm (BD
Bioscience) at 4uC for 20 min. After washing three times with
Perm Wash Buffer (BD Bioscience), cells were incubated with 1:40
dilution of monoclonal antibody to HIV-1 p24 (AG3.0) at 4uC for
30 min. Cells were washed again and incubated with 1:10 diluted
PE-conjugated anti-mouse IgG (BD Farmingen) at 4uC for
Antigen Incorporation at HVR2
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flow cytometer (BD Bioscience). Data were acquired with
CellQuest software and analyzed with FlowJo version 8.8.6
software.
Intracellular flow cytometry staining
Mice were vaccinated and boosted, as described above,
peripheral blood Gag-specific CD8 T cells were enumerated by
Flow cytometric analyses. Whole blood (100 ml) was collected in
heparinized PBS on days 26, 69, and 84 following initial
vaccination. Leukocytes were collected using lymphocyte separa-
tion medium (Mediatech. Inc. Manassas, VA). Cells were
collected and washed twice in 1%BSA, 2mM EDTA in PBS
and counted. One to two million lymphocytes were stained with
or without Gag Tetramer (APC) (created by Emory University)
and a cocktail of CD4-Alexa488 and CD8-PE antibodies (BD
Pharmingen, San Jose, California). Cells were washed with
1%BSA, 2mM EDTA in PBS. Cells were fixed with 1%
paraformaldehyde and subsequently analyzed for flow cytometry
on LSR II cytometer. Analysis of 3,000 CD8 T cells was collected
per sample.
Statistical evaluation
The data are presented as the mean 6 the standard error.
Statistical analyses were performed with the nonpaired two-tailed
Student t -test, assuming equal variance. Statistical significance
was defined as P,0.03.
Results
Construction of adenoviral vectors that contain HIV
antigen genes
After establishing the technical feasibilities allowing us to place
epitopes into HVR2 or HVR5[16,19], we sought to explore
whether we could present HIV antigens within the Ad protein
hexon as well as express HIV antigens as a transgene within Ad5.
The rationale for choosing a portion of the MPER (EKNEKEL-
LELDKWASLWNWFDITN), derived from gp41 for incorpora-
tion into the Ad capsid is based on the fact that the gp41 envelope
protein ectodomain is a target of three broadly neutralizing anti-
HIV-1 antibodies [32]. Gp41 antigenic function is conformation
dependent, therefore we planned to insert a linker sequence onto
the MPER core region in order to have the MPER epitope
presented on the Ad capsid as close to it’s natural conformation
as possible [33]. Our vaccine vector design also embodies the
incorporation of the HIV Gag gene within the Ad DE1 region.
The HIV Gag gene is a major structural protein of the HIV virus.
The Gag protein has been frequently used for HIV vaccine
schemes [34]. The DNA sequence corresponding to a 24 amino
acid region of the MPER plus a 15 amino acid linker was
amplified by PCR and then cloned into the hexon HVR2 shuttle
vector as previously described [16]. In addition, the HIV Gag
gene was subcloned into an DE1 shuttle vector under control of
the CMV promoter and transferred into the E1-deleted Ad5
genome (Ad5/HVR2-MPER-L15(Gag)) by homologous recom-
bination. In addition, a control vector was generated, which
contained an E1-deleted Ad5 genome in combination with
MPER within the hexon HVR2 region (Ad5/HVR2-MPER-
L15DE1). A control Ad genome expressing the Gag gene under
the CMV promoter with no hexon modification (AdCMVGag)
was generated in this study as well. The resulting Ad genomes
were partially sequenced to confirm that the correct genes were
incorporated. Subsequent transfection of HEK293 cells with the
resulting recombinant genomes resulted in rescue of the following
vectors: AdCMVGag, Ad5/HVR2-MPER-L15DE1, and Ad5/
HVR2-MPER-L15(Gag). In order to further confirm vector
identities, hexon and Gag-specific PCR analyses were performed
using genomic DNA from the purified virions (Figure 1A-B).
With regard to hexon-specific PCR, AdCMVGag was found to
have a wild type hexon PCR profile producing ,450 base pairs
(bp) PCR fragment using the hexon-specific primers designed to
amplify a regions between HVR2 and HVR5 (Figure 1A, lane 1).
A hexon specific PCR, on the Ad5/HVR2-MPER-L15(Gag)
construct revealed a 500 bp fragment, suggesting the expected
insertion (Figure 1A, lane 2). The addition of ,50 bp in
Figure 1A, lane 2 indicates the incorporation of the MPER-L15
DNA within the hexon region. Both AdCMVGag and Ad5/
HVR2-MPER-L15(Gag) were found to be positive in a Gag-
specific PCR assay, producing a ,1500 bp product with Gag-
specific PCR primers (Figure 1B, lanes 1–2, respectively). A
diagram depicting the vector construction of vectors used in this
study is illustrated in Figure 1C.
Figure 1. HIV envelope gp41 or Gag genes were genetically
incorporated into hexon hypervariable region 2 or adenovirus
DE1 region. Rescued viruses were amplified and viral DNA analyzed to
confirm stable modification of relevant genes. A) Hexon-specific PCR
primers confirmed incorporation of coding regions for MPER epitope
inserts at the hexon HVR2 site. Lane 1, AdCMVGag; lane 2, Ad5/HVR2-
MPER-L15(Gag). B) Gag-specific primers confirmed the incorporation of
coding regions for Gag inserts in the DE1 region. Lane 1, AdCMVGag;
lane 2, Ad5/HVR2-MPER-L15(Gag). C) Vectors used for this study are
depicted in this figure.
doi:10.1371/journal.pone.0011815.g001
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vectors
After successful incorporation of HIV genes we next sought to
verify expression of our transgene and capsid incorporation at the
protein level by Western blot analysis. HEK293 cells were infected
with unmodified Ad5 (as a negative control) or one of the HIV-
Gag containing viruses (Ad5/HVR2-MPER-L15(Gag) or Ad-
CMVGag, respectively. Cell lysates were prepared 24 hours
post-infection and subjected to Western blot analysis with anti-
Gag-specific antibody. Gag protein expression was evidenced by
the presence of a ,55 kDa molecular weight protein band in the
lysates from cells infected with either hexon-modified Gag
expressing vector Ad5/HVR2-MPER-L15(Gag) (Figure 2-A, lane
2) or the AdCMVGag (Figure 2-A, lane 3). As expected no Gag
protein expression was detected in the lysates from cells infected
with the unmodified Ad5 virus (Figure 2-A, lane 1).
In order to determine if the hexon-modified vectors were
presenting the MPER epitope within the hexon region, purified
unmodified Ad5, Ad5/HVR2-MPER-L15(Gag), or Ad5/HVR2-
MPER-L15DE1 were subjected to Western blot analysis with anti-
gp41 antibody. The MPER protein was detected as a 119 KDa
protein band associated with Ad5/HVR2-MPER-L15(Gag) or Ad5/
HVR2-MPER-L15DE1 particles, Figure 2-B, lanes 2 and 3,
respectively. The size of the 119 KDa band corresponds to the
expected size of the Ad5 hexon protein with MPER peptide
genetically incorporated into the HVR2 region. There was no MPER
protein detected on Ad5 wild type particles (Figure 2-B, lane 1).
HIV antigens, incorporated within HVR2, are exposed on
the virion surface
The foregoing studies validatedour ability to derive stable vectors
that incorporate MPER within hexon HVR2. Having established
the technical feasibilities that allowed us to place large epitopes
within hexon’s HVR2, we next sought to explore the functional
utilities of these modified vectors. To this end, we performed an
ELISA assay to verify that the HIV MPER motif in the HVR2 was
accessible on the virion surface (Figure 3A). In this assay, varying
amounts of purified viruses were immobilized in the wells of
an ELISA plate and incubated with anti-gp41 antibody. The results
showed significant binding of the anti-gp41 antibody to the
Ad5/HVR2-MPER-L15(Gag) and Ad5/HVR2-MPER-L15DE1,
whereas no binding was seen in response to AdCMVGag control.
These results indicate that the reactive MPER epitope was properly
exposed on the virion surfaces when incorporated within HVR2.
In order to determine the capability of the gp41-specific
antibody to bind capsid-incorporated antigen in a dose-dependent
manner a dose-response ELISA assay was performed with anti-
gp41 antibody. A single concentration of each of the following
viruses: AdCMVGag, Ad5/HVR2-MPER-L15(Gag), or Ad5/
HVR2-MPER-L15DE1 was applied to ELISA plates, followed by
the addition of serial dilutions of gp41 antibody. As predicted, the
anti-gp41 antibody bound to Ad5/HVR2-MPER-L15(Gag) and
Ad5/HVR2-MPER-L15DE1 in a dose dependent manner
(Figure 3B). Our data suggest that the MPER epitope is presented
within the hexon in its native conformation as it can be recognized
by a monoclonal HIV neutralizing antibody.
Growth kinetics of Anti-HIV vectors
Previous studies have shown that capsid modifications, as well as
some transgene incorporations, can compromise viral growth
characteristics. In order to ensure that normal viral growth was
not inhibited by epitope and/or transgene incorporation in the viral
particle/genome we performed growth kinetic assays on vectors
used in this study. To obtain a quantitative understanding of this
effect all respective vectors were titered in HEK293 cells until full
CPE was achieved in order to determine growth kinetics. The data
illustrates that the unmodified Ad5 had the highest titer
(,1610
14 IFU/ml) and produced full CPE at 96 hours post-
infection. AdCMVGag also produced full CPE at 96-hours post-
infection, however, AdCMVGag had a titer, several orders of
magnitude lower than that of the Ad5. Ad5/HVR2-MPER-
L15(Gag) showed comparable titers to that of AdCMVGag. The
controlvectorexpressing full-length envelope protein (AdCMVEnv)
reached full CPE after 120 hours post-infection. Ad5/HVR2-
MPER-L15DE1 yielded the slowest growth kinetics and relative
titer,reaching full CPEat192 hourspost-infection(Figure 4).These
growth kinetic patterns were similar to other capsid and transgene
modified vectors developed in our laboratory [31,35].
Thermostability of Anti-HIV vectors
Previous work has shown that capsid modifications may result in
the production of thermoliable vectors. Therefore, we performed
Figure 2. Western blotting confirmed the presence of HIV
genes within Ad vectors. A) In the assay, HEK293 cells were infected
with various vectors at 100 IFU per cell. Cell lysates were collected after
24 hours and equal protein amounts were separated on a 4 to 15%
polyacrylamide gradient SDS-PAGE gel. The proteins were transferred to
polyvinylidene fluoride membrane and then stained with Gag antibody.
Lane 1, Ad5 negative control; lane 2, Ad5/HVR2-MPER-L15(Gag); lane 3,
AdCMVGag. The arrow indicates Gag protein. B) 10
10 VP of Ad5 (lane 1),
Ad5/HVR2-MPER-L15(Gag) (lane 2), and Ad5/HVR2-MPER-L15DE1 (lane
3) were separated on 4 to 15% polyacrylamide gradient SDS-PAGE gel.
The proteins were transferred to polyvinylidene fluoride membrane
then stained with anti-gp41 antibody. The arrow indicates MPER protein
genetically incorporated into the hexon protein.
doi:10.1371/journal.pone.0011815.g002
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assays are important due to the complex nature of the
incorporated antigens, i.e. MPER and/or Gag. Hexon-modified
vectors, as well as controls vectors, were subjected to heating at
45uC for various time points (0,5,10, 20 and 45 minutes). These
vectors were then used to infect HEK293 cells. The viral infectious
titers were re-determined after heating using TCID50 assays.
According to the thermostability assay Ad5/HVR2-MPER-
L15DE1 was the least infectious of all the vectors, showing a
dramatic infectivity reduction relative to Ad5 following incubation
at 45uC for 20 or 45 minutes (Figure 5). These thermostability
results are similar to what we have observed with other transgene-
encoding or capsid-modified vectors in our laboratory [31,35].
Anti-MPER antibodies produced in mice after vaccination
To verify the immunizing potential of these vectors against
HIV we next sought to determine if they were capable of
eliciting an anti-HIV immune response in mice. Equal numbers
(1610
10VP) of the vectors were used to immunize BALB/c mice
via an intramuscular route. The sera were collected from mice
for ELISA assays at various days after priming and boosting.
Purified MPER antigenic peptide was bound to ELISA plates.
The plates were then incubated with the immunized mice sera.
Figure 4. Growth kinetics of modified Ad vectors. HEK293 cells
were infected with the vectors respectively, at 5 VP/cell. Cells were
harvested with medium at different time points until full CPE was
reached and total IFU were determined by TCID50. These data were
plotted as growth curves.
doi:10.1371/journal.pone.0011815.g004
Figure 5. Thermostability of modified Ad vectors. In these assays
various viruses were heat inactivated in PBS at 45uC for 0, 5, 10, 20 or 45
minutes. After heat inactivation, the virus were serially diluted and the
viral infectious titers were re-determined by TCID50 assays.
doi:10.1371/journal.pone.0011815.g005
Figure 3. HIV epitopes incorporated in HVR2 are exposed on
the virion surface. A) In the assay, varying amounts of AdCMVGag,
Ad5/HVR2-MPER24-L15(Gag), and Ad5/HVR2-MPER-L15DE1 were immo-
bilized in the wells of ELISA plates and incubated with anti-gp41
antibody. The binding was detected with an HRP-conjugated secondary
antibody. B) In the assay 6610
8 VP of either AdCMVGag, Ad5/HVR2-
MPER-L15(Gag), and Ad5/HVR2-MPER-L15DE1 were immobilized on an
ELISA plate followed by varying dilutions of gp41 antibody (1;6,000;
1:3,000;1:1,500; and 1:750). The binding was detected with an HRP-
conjugated secondary antibody.
doi:10.1371/journal.pone.0011815.g003
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antibody. The amount of anti-MPER antibody in the sera was
calculated based on a standard antibody curve dilution. The
data demonstrates no binding of the sera from mice immunized
with Ad5, AdCMVEnv, or AdCMVGag to the MPER on the
plates at any time point. On the contrary, immunization with
Ad that contains capsid-incorporated MPER antigen elicits an
anti-MPER specific response and allows the formation of
MPER-specific antibody in the serum (Figure 6). This immune
response is observed at the earliest time point that we observed,
which was 14 days post-prime (d.p.p). The peak immune
response was observed with the capsid incorporated MPER
vectors at 54 d.p.p, which also corresponds to 14 days post-
boost (d.p.b.). At 54 d.p.p the determined concentration of gp41
antibody was ,7 mg/ml. A slight decline of the MPER antibody
in the sera at 95 d.p.p was observed in the mice vaccinated with
capsid-modified vectors, which corresponded to 55 d.p.b. At
55 d.p.b. MPER antibody levels in the sera was determined to
be ,5 mg / m l .I ns u m m a r y ,A d 5 / H V R 2 - M P E R - L 1 5 DE1 and
Ad5/HVR2-MPER-L15(Gag) elicited an anti-gp41 response in
vaccinated mice. This MPER-specific response was increased
after boosting. It is importa n tt on o t et h a tt h ee n v e l o p e
expressed in AdCMVEnv was from the 89.6 HIV variant.
The epitope inserted into the Ad5 hexon and the peptide were
identical sequences with the 89.6 Env MPER region. The
transgene expressed from the Ad5 vector was 89.6 Env (i.e.
gp160), which is processed into gp120 and gp41. There were no
point mutations within the transgene expressed Env.
Isotype specific anti-MPER antibodies are produced in
mice after vaccination
We next performed experiments to determine the quantitative
aspects of the isotype-specific humoral immune responses that
were generated in response to the anti-HIV immunization
vectors. The sera were collected from mice for ELISA assays at
54 d.p.p and 14 d.p.b., as described previously. Purified MPER
antigenic peptide was bound to the plate. The plates were then
incubated with immunized mouse sera and the binding was
detected with HRP conjugated secondary antibody. Ad5/
HVR2-MPER-L15DE1 and Ad5/HVR2-MPER-L15(Gag) vec-
tors produced an isotype-specific anti-MPER humoral response
in vaccinated mice; whereas there was no isotype-specific
response seen in mice vaccinated with Ad5, AdCMVGag or
AdCMVEnv. The presence of isotypes IgG2b and IgG1
corresponds to Th1 and Th2 activation, respectively (Figure 7).
T cell activation is important for host protection against foreign
antigens.
Ad5 neutralization of hexon-modified vectors
The incorporation of the HIV-1 epitope into the hexon
protein of Ad5 may interfere with the viral infectivity and/or
reduce recognition by anti-Ad5 neutralizing antibodies (NAb).
We therefore compared infectivity of Ad5/HVR2-MPER-
L15(Gag) to that of the original AdCMVGag virus in the
presence or absence of anti-Ad5 NAb found in human ascites
that have been described previously [36]. In the absence of
ascites, the frequency of cells expressing Gag after infection with
AdCMVGag or Ad5/HVR2-MPER-L15(Gag) was 81.8% and
80.6% respectively, indicating that the incorporation of HIV-1
epitope into the hexon protein of the Ad5 vector did not reduce
virus infectivity (Figure 8A). Compared to the unmodified Ad5
vector, the presence of the HIV-1 epitope did not alter
neutralization by anti-Ad5 NAb present in the human ascites
(Figure 8B). Therefore the HIV-1 epitope did not facilitate
escape from pre-existing anti-adenoviral humoral immune
response, probably due to the polyclonal nature of the ascites
NAbs.
Figure 6. Adenovirus expressing capsid-incorporated HIV
antigens elicit an HIV humoral immune response. BALB/c mice
(n=8) were primed and boosted with 10
10 VP of Ad vectors. Pre-
immunization, post-prime, and post-boost sera was collected at various
time points for ELISA binding assays. 10 mMo fp u r i f i e dM P E R
(EKNEKELLELDKWASLWNWFDITN) antigenic peptide was bound to
ELISA plates. Residual unbound peptide was washed from the plates.
The plates were then incubated with immunized mice sera and the
binding was detected with HRP conjugated secondary antibody. OD
absorbance at 405nm represents MPER antibody levels in sera.
doi:10.1371/journal.pone.0011815.g006
Figure 7. Adenovirus expressing capsid-incorporated HIV
antigens elicit an HIV-specific isotype response. BALB/c mice
(n=8) were primed and boosted with 10
10vp of Ad vectors. Sera was
collected 54 d.p.p. and 14 d.p.b. for ELISA isotype binding assays.
10 mM of purified MPER (EKNEKELLELDKWASLWNWFDITN) antigenic
peptide was bound to ELISA plates. Residual unbound peptide was
washed from the plates. The plates were then incubated with
immunized mice sera followed by isotype specific antibodies. The
binding was detected with HRP conjugated secondary. OD at 405nm
represents of isotype-specific MPER antibody levels in sera.
doi:10.1371/journal.pone.0011815.g007
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vaccination with hexon-modified vectors
The previous experiments rely on the immune recognition of
capsid proteins and do not address the capacity of these modified
vectors to transduce cells and direct expression of the delivered
antigen-encoding transgenes in vivo. To test the capacity of our
hexon-modified vectors to deliver and induce expression of the
HIV Gag transgene, we measured the expansion of Gag-specific
CD8 T-cells at various consecutive time points following vaccine
priming and boosting, and later measured persistence of memory
T cells. Equal amounts of viral particles were used to immunize
mice. Blood was collected from mice on 21 d.p.p. and 26 d.p.b. T-
cells were subjected to Gag tetramer staining. The results in
Figure 9 illustrate that after mouse immunization with Ad5/
HVR2-MPER-L15(Gag) (5.63%) or AdCMVGag (4.05%) we
observed comparable Gag responses between these immunization
groups, this is an acceptable result in that the data shows that there
was not a loss of Gag response due to the incorporation of MPER
epitope within the hexon capsid. Mouse immunization with Ad5
vector resulted in background levels of T-cell activation (0.83%).
In addition, Ad5/HVR2-MPER-L15(Gag) (9.51%) vector allowed
boosting of the Gag transgene expression as compared to the
AdCMVGag vector (2.25%) (Figure 9), these results were
statistically significant at p,0.03. Intracellular IFNc staining in
tetramer positive CD8 T cells was observed for all groups (data not
shown), confirming the functional integrity of the expanded HIV
Gag-specific CD8 T cells.
Discussion
We have developed novel Ad vectors that have the potential to
optimize Ad vaccine approaches. This strategy involves inserting
antigenic epitopes into HVR2 or HVR5 regions of the Ad capsid
protein, hexon, to stimulate epitope-specific antibody responses
following vaccination. This method offers the ability to compare a
range of identical epitopes incorporated within HVRs for
antigenic optimization. Our current study is the first of its kind
to genetically incorporate HIV antigen within the Ad5 hexon
HVR2 alone or in combination with genomic incorporation of a
transgene for HIV antigen expression. In this study we successfully
incorporated the HIV MPER in the Ad5 HVR2 region as
evidenced by PCR, Western blot analysis, and the purified, whole-
virus ELISAs (Figures 1,2, and 3).
We believe that further characterization of the gp41 binding
antibodies is necessary; we performed additional ELISA experi-
ments using purified gp41 protein and sera from our vaccinated
mice. We were able to observe a slight binding of whole gp41
protein to the sera of mice vaccinated with Ad vector presenting
MPER within the hexon capsid (data not shown). We speculate
that this binding would have been increased if we were able to
obtain an identical purified gp41 protein as that presented with
our capsid-incorporated MPER sequence. This was not possible
due to the divergency of HIV protein structures and reagents
available. We also performed an ELISA assay with HIV pseudo
particles and sera from our vaccinated mice (data not shown). The
results were similar to that seen with purified gp41 protein. We
speculate that it is difficult to detect binding of gp41 to the HIV
particle due to the need of further optimization of this assay and/
or the limited amount of gp41 molecules available on a single HIV
virion (,10–30 Env (gp120 and gp41) molecules per virion).
It is more than likely that the MPER epitope inserted into the
Ad hexon is not presenting in the same conformation as it would
be presented within the context of an HIV virion, therefore there
are advantages and disadvantages to the antigen capsid-incorpo-
ration approach. The advantages of this approach include the fact
that it is obviously much easier to insert a small peptide from HIV
into hexon as compared to inserting a correctly folded version of
the full HIV protein into hexon (which would likely be impossible).
However, despite the fact that the MPER presentation might be
different with respect to Ad capsid incorporation compared to that
of MPER expressed on the HIV virion, we were able to detect the
presence of this epitope by the means of human HIV monoclonal
antibody 2F5, which recognizes 14 amino acids within MPER
(Figures 2B and 3). Whereas, we were not able to detect the
presence of MPER with the use of human HIV monoclonal
antibody 4E10, which binds a 6 amino acid linear epitope
immediately C-terminal to the 2F5 epitope and contained with
MPER (data not shown). These observations suggest that the
Figure 8. Comparison of infectivity between unmodified and hexon-modified Ad5 vectors. A) 293AD cells were infected at 10 MOI with
either AdCMVGag (top panel) or Ad5/HVR2-MPER-L15(Gag) (bottom panel) adenoviral vectors for 24 hours and then Gag expression was measured
by flow cytometry and analyzed with FlowJo version 8.8.6 software. The numbers indicate the percentage of cells positive for Gag expression. B) The
experiment was repeated as in A (one of three representative experiments is shown) in the presense or absense of serially-diluted neutralizing ascites.
The percentage (%) of infectivity was calculated by normalizing Gag expression to the infectivity in the absense of neutralizing ascites.
doi:10.1371/journal.pone.0011815.g008
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by the HIV virion. One advantage of the antigen capsid-
incorporation approach is that the non-glycosylated MPER may
be more immunogenic because of the absence of glycan-shielding.
With the hexon/peptide presentation approach we should be able
to address additional interesting questions, e.g. are there any
glycosylation sites within or around the MPER region that affect
immunogenicity. We plan to rigorously examine the ability of the
peptide presentation approach to produce neutralizing antibodies,
perhaps in a guinea pig or rabbit system.
When the MPER was incorporated into HVR2 in combination
with transgene expression, we observed growth kinetics (Figure 4)
and thermostability (Figure 5) changes similar to that of other
capsid-modified vectors generated in other studies [31,35].
Although, there appears to be substantial growth kinetic and
thermostability differences between Ad5/HVR2-MPER-L15(Gag)
and Ad5/HVR2-MPER-L15DE1 (Figures 4 and 5); there appears
to be no significant difference between cellular Gag immune
response generated from vaccination with Ad5/HVR2-MPER-
L15(Gag) and Ad5/HVR2-MPER-L15DE1 (Figures 6 and 7).
Most importantly, vaccination with hexon-modified vectors in this
study resulted in a humoral anti-HIV response. This is
noteworthy, because HVR2 has not been fully explored for
‘antigen capsid-incorporation’ strategies. Anti-MPER humoral
Figure 9. Capsid-modified vectors can induce a greater number of Gag-specific CD8 T cells and memory T cells than wild type
vectors. Cohorts of BALB/c mice (n=8) were immunized (prime) by injection of 10
10 vp i.m. with of one of the following Ad vectors: AdCMVGag,
Ad5/HVR2-MPER-L15(Gag), and Ad5/HVR2-MPER-L15DE1. Gag-specific T cells were detected in the peripheral blood of mice 2 weeks following the
initial vaccination, and given a boost immunization in the same manner on day 40. Peripheral blood Gag-specific CD8 T cells were enumerated
26 d.p.p, 69 d.p.p, and 84 d.p.b. A) Flow cytometric analyses bivariate pseudocolor plots are shown for a single mouse from each group for each time
point. B) The percent and total number of Gag-specific T cells per million lymphocytes are shown for each mouse and their level of T cells linked for
prime and boost time points. C) Paired scatter plots show significant differences in the percent and number of Gag-specific CD8 T cells induced by
either MPER-modified or AdCMVGag gene encoding vaccines. Statistical significance was determined by student’s t-test, (two-tailed) P,0.03.
doi:10.1371/journal.pone.0011815.g009
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istration. At 40 d.p.p the MPER response in mice, vaccinated with
hexon-modified vectors was approximately from 6 to 7 times
higher than when using AdCMVGag, AdCMVEnv, or Ad5
vector. This is a critical finding of our study. It appears that
vaccination with AdCMVEnv does not yield an antibody
response. This finding could be explained in various ways: (1)
since the HIV Env protein is a precursor protein that is catalyzed
by protease to give the final product gp41 and gp120, it is possible
that the production of gp120 is masking the antibody recognition
of gp41 [37]; (2) this finding might indicate that the antigen capsid-
incorporation strategy is superior to antigen transgene expression
with regards to generation an in vivo immune response to MPER
and/or other antigens [14]. In order to confirm the validity of the
results obtained from all vaccination groups, a separate set of
ELISA experiments were performed whereby sera from all
vaccinated mice were bound to unmodified Ad vectors. All of
the sera from the vaccinated groups bound unmodified wild type
Ad5 equally well, indicating equal vaccination by Ad5, Ad-
CMVGag, AdCMVEnv, Ad5/HVR2-MPER-L15(Gag) and
Ad5/HVR2-MPER-L15DE1 (data not shown). In addition, anti-
MPER IgG1 and IgG2b isotype-specific responses were observed
in mice vaccinated with the MPER capsid-modified vectors
(Figure 7). Similar results were seen with IgG2a (data not shown),
however; no MPER IgA-specific response was observed (data not
shown). We did not expect to find much of the MPER IgA-specific
immune response after vaccination with these vectors due to the
route of vector administration. However, we plan to further
investigate IgA-specific response in the context of targeted hexon-
modified vectors in combination with alternative routes of
administration. From a humoral immunity standpoint, IgA2
subclasses are reduced in saliva upon HIV infection, and total
secretory IgA levels are reduced at later disease stages. Salivary
IgA can be neutralizing to HIV-1 and HIV-2, and can block
epithelial transmigration. In this instance, salivary IgA can be
functional against HIV [38–40].
Figure 8, compares the infectivity of Ad5/HVR2-MPER-
L15(Gag) to that of the AdCMVGag vector in the presence or
absence anti-Ad5 NAb found in human ascites. Both vectors were
equally neutralized in the presence of human ascites fluid. We
expected that Ad5/HVR2-MPER-L15(Gag) would have been
neutralized to a lesser degree than AdCMVGag in the presence of
human ascites. However, since this was not the case, we speculate
that the polyclonal anti-Ad5 antibodies found in human ascites
fluid is not masked by the addition of a single epitope incorporated
within the hexon region. We also speculate that we might have
observed different results with this assay if we had used
monoclonal antibody, targeted to the hexon region where the
insert was incorporated. If a monoclonal antibody was used in the
presence of ascites fluid, Ad5/HVR2-MPER-L15(Gag) might
escape neutralization largely as compared to AdCMVGag.
However, this possibility was not explored further at this time
because it does not diminish the clinical benefit of these vectors.
Importantly, the Ad5/HVR2-MPER-L15(Gag) vector allowed
boosting of Gag transgene production, as compared to the wild
type Gag expressing vector (Figure 9), this result was statistically
significant at p,0.03. This is an important finding for two reasons:
(1) it indicates the potential for a second administration of the same
vector without the diminished production of transgene and (2) it
demonstrates that the incorporation of HIV epitopes within
HVR2 does not have a detrimental effect on in vivo transgene
production (Figure 9). We speculate that the MPER-modified
vector allows boosting compared to AdCMVGag, possibly because
the Ad5/HVR2-MPER-L15(Gag) Ad elicits less anti-Ad5 immune
response. It is possible that the MPER epitope reduced the
immunogenicity of the Ad5 vector. It is also possible that the anti-
MPER antibody fraction was not neutralizing with regards to the
hexon-modified Ad5 boost. Similar results were seen with
experiments performed by Abe and colleagues, their studies
support the concept that modified hexon thwarts Ad5 neutralizing
antibodies and promotes cellular immune responses [20].
There have been a range of studies that have now investigated
the viral antigen capid-incorporation strategy as a viable means to
improve vaccination in many disease or infection contexts
[4,14,15,17,18,21]. Due to the controversial HIV STEP trial
and the continuing HIV epidemic, some groups have employed
the antigen capsid-incorporation strategy to make strides against
HIV/AIDS by attempting to make a safe and effective HIV
vaccine [41,42]. The main vector systems that have been utilized
to derive a HIV vaccine include human rhinovirus (HRV) and Ad-
based vector systems [43]. With respect to the HRV system,
researchers have constructed HRV:HIV chimeras in an effort to
stimulate immunity against HIV-1 [44]. Furthermore or along
these lines, in an effort to develop HIV vaccines researchers within
this same group have generated combinatorial libraries of HRV
capid-incorporated HIV-1 gp41 epitope. Their results indicate
that they have been successful in eliciting antibodies whose activity
can mimic the 2F5 effect [45].
Commercial and clinical Ad development for HIV vaccines
have progressed preferentially more than vector systems such as
HRV because, the plasticity of Ad generally exceeds current
rhinovirus systems. For example, because it is a relatively small
RNA virus, the rhinovirus platform can display an array limited to
60 copies of a single HIV-1 epitope [44]. In comparison, the Ad
hexon-incorporation display platform could present an array of
720 HIV-1 epitope copies and the pIX incorporation display
platform could potentially present an array of 240 HIV-1 epitope
copies. Another significant difference between the two platforms is
in the number of locales that have been successfully utilized for
heterologous epitopes insertion. In this regard, to our knowledge,
the human rhinovirus 14-based platform utilizes a single-epitope
insertion site in the major immunogenic portion of the viral VP2
loop 2 [46,47]. In contrast, the Ad vector platform, could
potentially allow incorporation of the HIV-1 MPER epitope into
four structurally distinct locales, including: hexon, (HVR2 and
HVR5) [20], protein IX, penton base and/or fiber. Lastly, in
contrast to the rhinovirus that lacks this capacity, the Ad platform
has sufficient coding capacity allowing for HIV-1 transgene
expression in combination with presenting the same or a different
antigen on the viral capsid surface. Despite some of the noted
limitations with the rhinovirus platform, one of its attractive
features has been the previously mentioned development of
mutagenic libraries of human rhinovirus 14 chimeras that each
display randomized residues representing HIV-1 V3 or MPER
epitopes [48,49]. In this regard, it is worth mentioning that our lab
has previously developed a similar approach for screening and
identifying heterologous amino acid sequence insertions which
have been incorporated into the adenovirus fiber knob region
using a modified phage display approach [50-52]. Overall,
through extensive and ongoing vector development by both our
group and others, the Ad platform offers a dynamic level of
plasticity that translates into the advantage of multiple vaccine
development [20].
Taken together, our current study demonstrates that utilization
of the HVR2 for HIV MPER epitope incorporation, in
combination with HIV Gag transgene incorporation within the
Ad genome. Our previous work describes the precise optimal
antigen size and configuration for HVR5 capsid incorporation.
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internal gene loci, we will be able to establish novel vectors that
allow for the production of multivalent vectors that may act as a
vaccine ‘cocktail’. These vectors with capsid-incorporated antigens
will have the potential to vaccinate patients against HIV by
producing a robust anti-HIV humoral and T cell response. Our
data illustrates that there is a diverse immunological response/
profile of vaccination with capsid-modified vectors compared to
that of vector containing wild type hexon. This fact provides the
rationale that a heterologous prime boost strategy with our hexon-
modified vector followed by the wild type hexon vector could
potentially achieve an even greater anti-HIV immune response. In
addition, these vectors may have great potential to circumvent the
drawbacks seen in the general population related to Ad5 PEI. Our
future plans include transitioning these vectors to a ‘gutless’
[53–57] system in order to determine the duration and quality of
HIV antibody production. In combination with the ‘gutless
system’ we plan to decrease Ad5 PEI through the use of chemical
conjugates such as Polyethylene Glycol [58,59] and/or Ad vector
chimeras.
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